欧洲泌尿外科学会更新指南:同步转移性透明细胞肾癌的减瘤性肾切除术
该指南基于CARMENA试验数据更新,指出对于需要药物治疗的中危和低危转移性肾细胞癌患者,立即行减瘤性肾切除术不应再被视为标准治疗;同时应关注低危患者得知切除原发肿瘤无益时的心理负担。
要点
- 中危和低危转移性肾细胞癌需药物治疗者,不推荐立即行减瘤性肾切除术。
- CARMENA试验比较了单纯全身治疗与减瘤性肾切除术后全身治疗。
- 需关注低危患者得知切除原发肿瘤无益时的心理负担。
核心结论
- 对于需要药物治疗的中危和低危转移性肾细胞癌患者,立即行减瘤性肾切除术不应再被视为标准治疗。
研究设计与样本
- 欧洲泌尿外科学会基于CARMENA试验数据制定的指南更新。
主要发现
- CARMENA试验比较了单纯全身治疗与减瘤性肾切除术后全身治疗。
关键数值与推荐
- 中危和低危转移性肾细胞癌需要药物治疗时,不推荐立即行减瘤性肾切除术。
临床怎么用
- 对需要药物治疗的中危和低危转移性肾细胞癌患者,不应将立即减瘤性肾切除术作为标准治疗。
- 与低危患者沟通切除原发肿瘤无益时,需考虑其心理负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data. PATIENT SUMMARY: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered.
引用
- Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol. 2018. PMID: 30177291. doi:10.1016/j.eururo.2018.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。